VAGINAL CYTOLOGIC EVALUATION AS A PRACTICAL LINK BETWEEN HORMONE BLOOD-LEVELS AND TUMOR HORMONE DEPENDENCY IN EXCLUSIVE MEDROXYPROGESTERONE TREATMENT OF RECURRENT OR METASTATIC ENDOMETRIAL ADENOCARCINOMA
- 1 January 1977
- journal article
- research article
- Vol. 21 (2) , 218-224
Abstract
In 100 patients treated with 1 medroxyprogesterone a week for disseminated or recurrent endometrial adenocarcinoma, vaginal cytohormonal evaluation seemed to be an important predictive factor of hormone dependency and tumoral responsiveness to progestational therapy. Almost all 51 patients, representing the responsive group, revealed an evident drop of the Karyopyknotic Index and a complete shift to the left of the Maturation Index. Both cytohormonal and tumoral response to medroxyprogesterone seemed directly related to estrogen-progestogen interaction on a cellular level. The striking LH [luteinizing hormone] response in the responsive group has previously not been integrated in this mechanism of action.This publication has 9 references indexed in Scilit:
- MEDROGESTONE THERAPY IN ADVANCED ENDOMETRIAL ADENOCARCINOMA1967
- PROGESTERONE CAPROATE IN TREATMENT OF ENDOMETRIAL CANCER1966
- Use of progestational agents in the management of endometrial cancerCancer, 1965
- PROGESTERONE AND PROGESTATIONAL COMPOUNDS IN THE TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMAActa Endocrinologica, 1965
- Progestatinal drugs in the management of endometrial cancerMetabolism, 1965
- ROLE OF PROGESTERONE IN HUMAN ENDOMETRIAL CANCER1965
- EFFECT OF 17-ALPHA-HYDROXYPROGESTERONE 17-N-CAPROATE ON VARIOUS PELVIC MALIGNANCIES1964
- URINARY EXCRETION ASSAYS OF PITUITARY LUTEINIZING HORMONE (LH) RELATED TO ENDOMETRIAL CARCINOMA1963
- CLINICAL AND HISTOPATHOLOGIC EVALUATION OF EFFECT OF 17-ALPHA-HYDROXYPROGESTERONE-17-CAPROATE ON ENDOMETRIAL CARCINOMA1961